Angiotech CEO Hunter leaves; Bailey takes charge
This article was originally published in Scrip
Executive Summary
Dr William Hunter has resigned his position as president and CEO of Angiotech Pharmaceuticals, a pharmaceutical and medical device company developing treatment solutions for diseases and complications associated with medical device implants, surgical interventions and acute injury. CFO Thomas Bailey will serve as interim president and CEO, while director of corporate development Tammy Neske has been promoted to chief business officer.